within Pharmacolibrary.Drugs.ATC.D;

model D04AA14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 18 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Clemastine is a first-generation antihistamine of the ethanolamine class. It is primarily used for symptomatic relief of allergic conditions such as rhinitis and urticaria, and sometimes as an antipruritic (for itching). Clemastine is available in some countries as an over-the-counter or prescription medication, but its use has decreased in favor of non-sedating antihistamines.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult individuals; literature lacks robust, directly reported model-based PK data.</p><h4>References</h4><ol><li><p>Odell, EP, et al., &amp; Ostrem, BEL (2024). Minimum effective dose of clemastine in a mouse model of preterm white matter injury. <i>Pediatric research</i> 96(4) 933–941. DOI:<a href=&quot;https://doi.org/10.1038/s41390-024-03326-w&quot;>10.1038/s41390-024-03326-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38942888/&quot;>https://pubmed.ncbi.nlm.nih.gov/38942888</a></p></li><li><p>Schran, HF, et al., &amp; Gelbert, MB (1996). The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. <i>Journal of clinical pharmacology</i> 36(10) 911–922. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1996.tb04758.x&quot;>10.1002/j.1552-4604.1996.tb04758.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8930778/&quot;>https://pubmed.ncbi.nlm.nih.gov/8930778</a></p></li><li><p>Törneke, K, et al., &amp; Broström, H (2003). Pharmacokinetics and pharmacodynamics of clemastine in healthy horses. <i>Journal of veterinary pharmacology and therapeutics</i> 26(2) 151–157. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2885.2003.00460.x&quot;>10.1046/j.1365-2885.2003.00460.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12667185/&quot;>https://pubmed.ncbi.nlm.nih.gov/12667185</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D04AA14;
